Taeyoung to Sack Executives, Cut Employees' Salaries to Save Company 
Will global oil supply be at risk if Iran and Israel pull the Middle East into war? 
SPC Group’s Paris Baguette Inaugurates First Bakery Shop in the Philippines 
Economists say Australia shouldn’t try to transition to net zero by aping the mammoth US Inflation Reduction Act 
LVMH Adds Bernard Aranault’s Sons Frederic and Alexandre Arnault to the Board 
‘They don’t have enough’ – schools in England are running food banks for families 
Adidas Unveils Innovative Team Kits for Paris 2024 Olympics and Paralympics 
LG Electronics Eyes $1 Billion Through Bond Deal 
Canada Set to Enforce OECD Crypto Tax Standards by 2026 
Samsung Targets Beijing’s EV Semiconductor Market at Auto China 2024 
Industrialisation is still vital to economic development but some countries are struggling to reap its benefits 
Nissan Cuts Profit Forecasts Amidst Sales Slump and Natural Disaster 
How India’s economy has fared under ten years of Narendra Modi 
Celltrion announced that its COVID-19 test kit called DiaTrust has been given conditional approval by South Korea’s drug safety board. The biopharmaceutical company headquartered in Incheon shared the news on Monday, April 3.
The new coronavirus test kit
The Korea Herald reported that DiaTrust was jointly developed by Celltrion and Humasis, an R&D company based in S. Korea as well. The two sides made this antigen test kit that is said to be capable of detecting the newest COVID-19 variants that originated in Brazil and the U.K.
The rapid test kit can show results in as short as 15 minutes. It will identify the particular antigens of coronavirus that are present in the specimen collected from a person through a sterile nasal swab. Celltrion explained that what sets this kit apart from the other of its kind is that it uses a dual antigen method that can spot both N and S antigens.
“Celltrion will speed up its supply of COVID-19 test kit in the domestic market,” a company official stated. “The firm will submit additional clinical data concerning the test kit to the Ministry of Food and Drug Safety within three months.”
The biopharma company is expecting a surge in global demand for the DiaTrust COVID-19 test kit in the near future. In fact, in the U.S., the kit already received emergency use approval from the Food and Drug Administration (FDA). In April, the agency gave its authorization based on the clinical trial results that Celltrion submitted, and it is now reviewing additional clinical data.
Self-test kit to be marketed after gaining FDA nod
Celltrion was granted conditional approval for DiaTrust last week and to get its formal authorization from S. Korea’s Ministry of Food and Drug Safety. It needs to submit more clinical data within three months, as per the Korea Bio Medical Review.
It was added that the company is planning to supply the COVID-19 test kits via its subsidiary firm, Celltrion Pharm. It is also looking at other distribution outlets such as iMarket Korea.
Meanwhile, Celltrion’s new DiaTrust COVID-19 Ag home test kit was said to have shown results with high accuracy. However, it pointed out that suspected coronavirus patients with an obvious epidemiological connection to infection should get PCR tests at authorized screening centers set up by health authorities because the kits are just a supportive tool.
